Background: Interindividual differences in DNA repair capacity may influence cancer risk. We tested whether the nucleotide excision repair pathway was deficient in breast cancer case patients by analyzing sister pairs. Methods: Cell lines derived from sisters discordant for breast cancer (137 families containing 158 case patients and 154 control sisters) were obtained from the Metropolitan New York Registry of Breast Cancer Families. Lymphoblastoid cells were treated with benzo[a]pyrene diolepoxide (BPDE) for 30 minutes and were either harvested immediately or were washed and cultured in complete medium for 4 hours to allow DNA repair. Immunofluorescence using a polyclonal anti-BPDE-DNA primary antibody was used to quantify BPDE-DNA adducts. Percent DNA repair capacity was calculated from the difference between staining immediately after treatment minus that after 4 hours of repair, divided by the initial damage and was categorized into quartiles based on control values. Odds ratios and 95% confidence intervals (CIs) were calculated using conditional logistic regression models adjusted for age at blood donation, body mass index, and smoking. Statistical tests were two-sided. Results: Mean percent DNA repair capacity was lower in breast cancer case patients than in control subjects (difference ‫؍‬ 8.6, 95% CI ‫؍‬ 4.3 to 13.8, P ‫؍‬ .001). Using the quartile with the highest percent DNA repair capacity as the referent group, adjusted odds ratios of breast cancer increased from 1. 
Interindividual differences in DNA repair capacity have been suggested to be an important source of variability in cancer risk (1) . A number of epidemiologic studies, primarily of lung and skin cancer, have suggested that deficiency in DNA repair capacity contributes to the accumulation of DNA damage and accelerates the gene rearrangements, deletions, insertions, and amplifications involved in human carcinogenesis (1, 2) . In studies of breast cancer DNA repair capacity has been investigated using lymphocytes treated in vitro with DNA-damaging agents and then measuring cytogenetic damage or DNA strand breaks with the Comet assay (1, (3) (4) (5) (6) DNA damage was evaluated immediately after treatment, using a mutagen sensitivity assay, or also after allowing cells time to repair the induced damage. The host cell reactivation assay has also been used to monitor the ability of lymphocytes to repair a transfected plasmid with DNA damage (7, 8) . All of these studies found increased breast cancer risk in those with greater sensitivity to mutagens or poorer DNA repair capacity.
In this study, we used sister sets discordant for breast cancer to evaluate the hypothesis that reduced DNA repair capacity in the nucleotide excision repair pathway that removes bulky DNA adducts is associated with cancer risk. A major strength of the familybased design is that it eliminates potential confounding related to population admixture. Sister sets can also reduce potential confounding due to differences in genetic susceptibility as well as behavioral and lifestyle factors, which cluster within families. DNA repair capacity was assayed by measuring the removal of in vitroinduced benzo [a] pyrene diolepoxide (BPDE)-DNA adducts in lymphoblastoid cell lines generated from each subject's blood. BPDE is a carcinogenic metabolite of benzo [a] pyrene that is a common environmental pollutant present in cigarette smoke, ambient air, and various foods. Although prior studies have suggested that polycyclic aromatic hydrocarbons may be related to breast cancer risk (9, 10) , we used BPDE for these studies because of its ability to induce damage that is repaired by the nucleotide excision repair pathway.
Two prior studies have used BPDE as a test mutagen in breast cancer case patients and control subjects. In one study, lymphocytes were treated with BPDE, and DNA repair was assessed using the mutagen sensitivity assay (5) . In the other, plasmid DNA was damaged with BPDE, and repair was measured using the host cell reactivation assay (8) . In both studies, higher mutagen sensitivity and poorer repair, respectively, were observed in case patients compared with control subjects. We previously reported results on a pilot study of 50 subjects (25 sets of paired sisters) (11) and found poorer repair in case patients. We have now expanded the study to 137 new families, excluding the previous 50 subjects.
SUBJECTS AND METHODS

Study Population
The study population was selected from families participating in the Metropolitan New York Registry of Breast Cancer Families, one of six sites funded by the National Cancer Institute (NCI) as a part of the Breast Cooperative Family Registry (CFR) (www.cfr.epi.uci.edu) (12) . The study was approved by Columbia University's Internal Review Board; written informed consent was obtained from all subjects, and strict quality controls and safeguards were used to protect confidentiality. Families were eligible to participate in the New York Registry of Breast Cancer Families if they met one of the following criteria: 1) have a female relative with breast or ovarian cancer diagnosed before age 45 years, 2) have a female relative with both breast and ovarian cancer diagnosed regardless of age at diagnosis, 3) have two or more relatives with breast or ovarian cancer diagnosed after age 45 years, 4) be a male with breast cancer diagnosed at any age, or 5) have a family member with a known BRCA mutation. The present study included all families for whom lymphoblastoid cell lines were available for at least two sisters discordant for breast cancer and consisted of 158 case patients and 154 control subjects from 137 families out of the total of 1250 Registry families. One hundred and seventeen families had one set of sisters and the remaining 20 families had two or three case patients and/or control subjects in the family.
Several questionnaires were administered to each consenting, participating family member on recruitment into the Registry, including a family history instrument that collected information on history of all cancers; an epidemiology questionnaire that collected information on demographics, ethnicity, smoking, alcohol consumption, reproductive history, hormone use, weight, height, and physical activity; and a self-administered food frequency questionnaire. Blood was collected from all participating family members at the time of recruitment. For case patients, blood was collected 5 years after diagnosis, on average.
Cell Culture
Two reference human lymphoblastoid cell lines (GM01989 and GM02485; National Institute of General Medical Sciences Human Genetic Mutant Cell Repository, Coriell Institute for Medical Research, Camden, NJ) and cell lines developed from lymphocytes of sisters in the Breast CFR (as mentioned above) were used. The GM01989 cell line was established from an apparently normal subject, and the GM02485 cell line was from a subject with xeroderma pigmentosum complementation group D. All cell lines from the sisters in the study were developed from frozen lymphocytes stored from less than 1 to 5 years, with some transformations carried out at Coriell Institute and others in our laboratory, both using Epstein-Barr virus isolated from the marmoset line B95-8 and the same procedure (13) . Cells were grown in suspension in 75-cm 2 tissue culture flasks (Nalge Nunc International, Rochester, NY) in RPMI-1640 medium supplemented with 1% L-glutamine, antibiotics (Cellgro Mediatech, Herndon, VA), and 10% fetal bovine serum (Fetalclone I, HyClone, Logan, UT) at 37°C with 5% CO 2 for 1 week.
DNA Damage and Repair
The DNA repair assay was carried out essentially as described (11) . Lymphoblastoid cell lines from sisters discordant for breast cancer were assayed together with the two reference cell lines (DNA repair-proficient line, GM01989, and-deficient line, GM02485). Cells (1.5 ϫ 10 7 ) were suspended in 15 mL of serum-free RPMI. Immediately before treatment with (Ϯ)-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene (the anti isomer) (BPDE; NCI Chemical Carcinogen Repository, Midwest Research Institute, Kansas City, MO), 5 mL of the cell suspension was prepared for immunohistochemical analysis by centrifuging at 20°C for 10 minutes at 1000g, redissolving in 50 L and dropping approximately 3 L onto microscope slides, and spreading the cells. The remaining cells (1.0 ϫ 10 7 in 10 mL) were treated with 5 M BPDE by adding 10 L of 5 mM BPDE in tetrahydrofuran and culturing for 30 minutes. The cells were then centrifuged as above and washed with phosphate-buffered saline (PBS). Half of the cells were immediately prepared for immunohistochemical analysis as above, and the remainder were cultured in 5 mL of complete medium with fetal bovine serum for 4 hours to allow the cells to repair the damage before slide preparation. The reference cell lines were assayed with each batch of experimental samples, and both members of each sister set were tested in the same experiment. The laboratory investigator who performed the assays was blinded to case-control status.
Immunohistochemical Analysis of BPDE-DNA Damage
The immunohistochemical analysis method performed has been described previously (11, 14) . Briefly, slides were treated with approximately 100 L of RNase (0.1 mg/mL in Tris buffer, pH 7.5) for 1 hour at 37°C, then with 100 L of proteinase K (10 g/mL in Tris buffer, pH 7.5) for 10 minutes, and with 100 L of 4 N HCl for 10 minutes at room temperature followed by neutralization with 100 L of 50 mM Tris base for 5 minutes at room temperature. Slides were washed twice by immersing in PBS for 5 minutes. Slides were blocked with 100 L of 10% normal goat serum in Tris buffer, pH 7.5, for 45 minutes at 37°C. Cells were then incubated with 100 L of rabbit anti-BPDE-DNA polyclonal antiserum #1 (15) at a 1:500 dilution overnight at 4°C. Next, cells were incubated with 100 L of secondary fluorescein isothiocyanate-conjugated goat anti-rabbit IgG (ICN Biomedicals, Aurora, OH) at a 1:200 dilution for 45 minutes at 37°C. Cells were counterstained with 100 L of 1 g/mL propidium iodide (Sigma, St. Louis, MO) in PBS for 45 seconds at room temperature. The average nuclear fluorescence intensity for a minimum of 50 randomly selected cells from fields that displayed strong propidium iodide staining (5 cells in each of 10 fields) was determined using a Nikon Eclipse 600 microscope (Nikon, Melville, NY) mounted with a charge-coupled display camera (Hamamatsu C4742-95 [ORCA-100], Bridgewater, NJ) and equipped with image analysis software (MetaView Imaging System, Universal Imaging, West Chester, PA). Fluorescence intensity was collected as an "average gray value," a measure of relative fluorescence intensity.
Percent DNA repair capacity was calculated using the average gray value as the measure of fluorescence intensity of nuclear staining. The fluorescence intensity of each subject's untreated cells was subtracted from the fluorescence intensity of her BPDE-treated cells stained immediately after treatment and after 4 hours of repair. DNA repair capacity was calculated from the formula percent DNA repair capacity equals [(I 0 Ϫ I C ) Ϫ (I 4 Ϫ I C )]/(I 0 Ϫ I C ) ϫ 100% where I 0 is the intensity of treated cells immediately after treatment, I 4 is that after 4 hours of repair, and I C is that for untreated control cells. The daily variation in the determination of the percent DNA repair capacity was 8. 
Statistical Methods
Student's t tests and one-way analysis of variance were used to compare mean percent DNA repair capacity between case patients and control subjects. In addition to these univariate analyses, the differences between sister sets were examined using conditional logistic regression (16) . In these regression models, the association between the percentage of adducts removed and the participant's status was estimated while simultaneously adjusting for potential confounding variables such as age at blood donation, current body mass index (BMI, [weight in kilograms]/[height in meters squared]), and smoking. Odds ratios (ORs) and P trend values were calculated using maximum likelihood methods (16) . Differences were considered statistically to be significant if PϽ.05. Both median and quartiles of DNA repair capacity in control subjects were used as cut points for the calculation of odds ratio (see Table 2 ). Medians were used to categorize the intervals between age at diagnosis and age at interview, BMI, and smoking level.
RESULTS
No statistically significant differences in demographic or lifestyle characteristics and age at blood donation or interview were observed between case patients and control subjects (Table 1 ). The mean age Ϯ standard deviation (SD) at breast cancer diagnosis for case patients was 43.2 Ϯ 9.3 years. For case patients, the average interval between age of diagnosis and age at enrollment in the Registry was 6 years. The mean age Ϯ SD at interview was 49.1 Ϯ 10.3 years for case patients and 48.9 Ϯ 10.8 years for control subjects. Ages at blood draw were also similar for case patients (mean Ϯ SD ϭ 49.7 Ϯ 10.2 years) and control subjects (mean Ϯ SD ϭ 49.6 Ϯ 10.7 years, P ϭ .72). Approximately 45% of case patients and control subjects were ever smokers, with current smokers in both groups smoking an average of approximately 15 cigarettes per day. BMI also did not differ statistically significantly between case patients (mean Ϯ SD ϭ 25.7 Ϯ 5.6) and control subjects (mean Ϯ SD ϭ 25.5 Ϯ 4.5). Approximately 75% of subjects were Caucasian and the remainder were African American, Hispanic, or Asian.
BPDE-DNA damage levels measured immediately after treatment (I 0 Ϫ I C ) were not statistically significantly differ- ‫ء‬Cell lines were obtained from 137 families in the Metropolitan New York Registry of Breast Cancer Families. Medians were used to categorize the intervals between age at diagnosis and age at interview, body mass index (BMI), and smoking level. SD ϭ standard deviation.
†P value using two-tailed Student's t test. ‡P value using two-sided one-way ANOVA. §Includes African American, Hispanic and Asian; ethnicity was missing for one family.
ent between case patients and control subjects (P ϭ .36, data not shown). We separately analyzed the data from the 117 families with a single set of sisters (data not shown) and found results essentially identical to those in the whole data set. Therefore, only the results from the full data set are presented (Table 1) . We also separately analyzed those who provided blood samples within 5 years of or more than 5 years after diagnosis and saw no difference (data not shown). DNA repair capacity was statistically significantly lower in breast cancer case patients than in their control sisters (difference ϭ 8.6, 95% CI ϭ 4.3 to 13.8, P ϭ .001). Casecontrol differences in DNA repair capacity were also analyzed after stratification by age, ethnicity, and smoking status. In all age groups, DNA repair capacity was higher in control subjects than in case patients, but these differences were statistically significant only in the younger age groups. The largest difference in mean percent DNA repair capacity between case patients and control subjects was among women younger than age 40 at blood donation (P ϭ .005). Stratification by ethnicity or smoking status did not alter the results. For BMI, case-control differences were statistically significant in women with a BMI of 25 or greater but not in those with a BMI of less than 25. The association of age, ethnicity, BMI, and smoking status on DNA repair capacity was also investigated (Table 1) . Case patients younger than 50 years had lower percent DNA repair capacity than case patients 50 years old or older, although this difference was not statistically significant (difference ϭ 5.7, 95% CI ϭ 3.4 to 15.2, P ϭ .235). For control subjects, in contrast, percent DNA repair capacity was higher in younger than in older subjects, but again, the difference was not statistically significant (P ϭ .164). Comparing case patients and control subjects, statistically significant differences were observed in those younger than 40 years. There were no statistically significant differences in percent DNA repair capacity by ethnicity, BMI, or smoking status in either case patients or control subjects, although differences between case patients and control subjects were observed in nonCaucasians and those with a BMI of 25 or greater.
When percent DNA repair capacity values were dichotomized using the median value in control subjects, values below the median percent DNA repair capacity were associated with an elevated breast cancer risk (crude OR ϭ 2.29, 95% CI ϭ 1.38 to 3.79; Table 2 ). After adjustment for age at blood donation, BMI, and smoking status, the OR was 2.43 (95% CI ϭ 1.44 to 4.08). Furthermore, categorizing percent DNA repair capacity values into quartiles based on data in control subjects resulted in a statistically significant dosedependent association between deficient DNA repair capacity and breast cancer risk. Using the quartile with the highest percent DNA repair capacity as the referent group, adjusted ORs increased from 1.23 (95% CI ϭ 0.57 to 2.65) to 2.38 (95% CI ϭ 1.17 to 4.86) and 2.99 (95%CI ϭ 1.45 to 6.17) as percent DNA repair capacity decreased (P trend ϭ .002). Similar results were obtained when the analysis was limited to the 117 families with a single set of sisters; ORs increased from 1.46 (95% CI ϭ 0.62 to 3.44) to 1.80 (95% CI ϭ 0.77 to 4.20) and 2.77 (95% CI ϭ1.21 to 6.37) as DNA repair capacity decreased (P trend ϭ.029).
DISCUSSION
We used the removal of BPDE-DNA adducts in lymphoblastoid cell lines as an indicator of DNA repair capacity in the nucleotide excision repair pathway in a case-control study of sisters discordant for breast cancer. Percent DNA repair capacity of breast cancer patients statistically significantly differed from that of their sister control subjects without breast cancer, with a more than twofold increase in risk with deficient DNA repair capacity, defined as below the median in control subjects. Furthermore, when DNA repair capacity data were stratified into quartiles based on values in control subjects, a statistically significant dose-response relationship was observed; breast cancer risks were threefold higher among women with the poorest repair capacity than among those with the highest.
In analysis stratified by age, case patients younger than 50 years showed a somewhat lower DNA repair capacity than those older than 50 years and, in control subjects, percent DNA repair capacity decreased with age. As a result, the largest difference in DNA repair capacity between case patients and control subjects was in the youngest age group. The observation in control subjects is in agreement with other studies showing decreased DNA repair capacity with increasing age in the general population (17, 18) . In addition, Ramos et al. (7) observed that younger breast cancer case patients had a more substantial reduction in capacity to repair UV damage compared with age-matched control subjects than did older case patients and control subjects. In a study of basal cell carcinoma, older patients (aged 40 years and older) also had statistically significantly higher DNA repair capacity compared with their matched control subjects and a higher DNA repair capacity than younger case patients, although this was not statistically significant (19) . With regard to ethnicity, the DNA repair capacity differences were similar between Caucasians and non-Caucasians (African Americans, Hispanics, and Asians) within case patients or control subjects †Crude odds ratio determined using a conditional logistic regression model. ‡Multivariable conditional logistic regression adjusted for age at blood donation, body mass index, and smoking status.
§Wald test for trend was performed using the conditional logistic regression model based on the medians of quartiles of DNA repair capacity in control subjects.
although the number of non-Caucasians was small (Table 1) . Nor was there an association of smoking with DNA repair capacity in either case patients or control subjects-the difference in percent DNA repair capacity between smokers and nonsmokers was not statistically significant. Similar results have been observed in a study of upper aerodigestive tract cancer (20) .
A unique strength of this study was the family-based design using sisters from the same families as case patients and control subjects. Because each case patient's control subject was her sister, any potential confounding related to population admixture was eliminated. Using sisters as control subjects also reduces some of the confounding due to differences in genetic susceptibility as well as behavioral and lifestyle factors that cluster within families. The fact that such large differences in DNA repair capacity were observed in sisters that have other risk factors in common (family history, lifestyle, and behavior) further strengthens these results.
Another strength of our study is that our measurement of DNA repair capacity was more specific than that of many other studies. Most prior studies analyzed mutagen sensitivity, which is a combined measure of DNA damage formation and repair capacity immediately after treatment. Hence, those studies could not distinguish between actual repair processes and other exogenous and endogenous factors modifying the initial level of DNA damage, such as decomposition of the mutagen in aqueous solution or detoxification processes. In contrast, by treating cells with a direct-acting carcinogen, we avoided potential bias due to individual differences in efficiency of metabolism of the parent mutagen, benzo[a]pyrene, into a reactive form. The assay used in the present study allows independent estimation of individual sensitivity to the test mutagen and DNA repair capacity. Individual sensitivity levels were estimated by measuring BPDE-DNA adducts in cells harvested immediately after mutagen treatment, but no differences were observed between case patients and control subjects.
This study also has several limitations. Ideally, DNA repair capacity should be measured in the target tissue, mammary epithelial cells. However, most studies use fresh or cryopreserved lymphocytes because these are more readily available than target tissue. In this study, transformed lymphoblastoid cell lines generated from peripheral lymphocytes were used because the cell lines were readily available as a core resource of the Breast CFR. The advantage of using lymphoblastoid cell lines is that they are an unlimited resource and can be thawed for use whenever needed. Our finding that these cell lines allow the detection of differences in DNA repair capacity between case patients and control subjects widely expands the types of repair studies that can be carried out. Indeed, prior studies have successfully used lymphoblastoid cell lines in establishing DNA repair assays (21) , and a correlation between DNA repair capacity in primary lymphocytes and lymphoblastoid cell lines has been observed (22) .
Another limitation is that blood samples were collected from case patients after diagnosis; 50% were collected more than 5 years after diagnosis. However, we separately analyzed those who provided blood samples within 5 years after diagnosis and those who provided blood more than 5 years after diagnosis and saw no difference in results.
In summary, these data support the hypothesis that deficient DNA repair capacity is associated with susceptibility to breast cancer and may be a valuable in vitro biomarker to identify high-risk subjects, especially in familial breast cancer families. It is unclear at this time whether there are any interventions that could alter DNA repair capacity and what effect such interventions might have on risk.
